Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients

Mikako Warren, Rajyalakshmi Luthra, C. Cameron Yin, Farhad Ravandi, Jorge E. Cortes, Hagop M. Kantarjian, L. Jeffrey Medeiros, Zhuang Zuo

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

FMS-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in acute myeloid leukemia and is associated with worse clinical outcome. Changes in FLT3 mutation status can occur during the course of disease, but the clinical impact of a change is unclear. We retrospectively reviewed 3555 acute myeloid leukemia patients, who have been assessed for FLT3 mutation at our institution between May 2002 and January 2011. We found that 42 (6.2%) out of 680 patients with FLT3 mutation experienced a change of FLT3 mutation status. In all, 36 patients with wild-type FLT3 at the time of initial diagnosis gained mutation (Negative/Positive) and six initially FLT3-mutated patients became wild type during their following relapses (Positive/Negative). The 5-year survival of these patients was similar to that of patients with persistently wild-type FLT3 (Negative/Negative; P=0.464), and significantly better than patients who had stable FLT3 mutation during their disease course (Positive/Positive; P=0.001). However, after mutations became detectable in the Negative/Positive group, the forward survival of these patients tracked that of the Positive/Positive group after relapse (P=0.761). In addition, we did not find a significant difference in survival between patients with internal tandem duplications and those with point mutations in the tyrosine kinase domain of the FLT3 gene. These results suggest that FLT3 mutations are unstable and that there is potential clinical value in continuously monitoring FLT3 mutation status.

Original languageEnglish (US)
Pages (from-to)1405-1412
Number of pages8
JournalModern Pathology
Volume25
Issue number10
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

Keywords

  • acute myeloid leukemia
  • FMS-like tyrosine kinase (FLT3)
  • mutation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients'. Together they form a unique fingerprint.

  • Cite this

    Warren, M., Luthra, R., Yin, C. C., Ravandi, F., Cortes, J. E., Kantarjian, H. M., Medeiros, L. J., & Zuo, Z. (2012). Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Modern Pathology, 25(10), 1405-1412. https://doi.org/10.1038/modpathol.2012.88